Abstract
Objective: Tuberculosis (TB) is a highly prevalent infectious disease caused by Mycobacterium tuberculosis. The recommended TB treatment is acombination of various antibiotics in the form of a fixed-dose combination tablet or kombipak; however, this increases the prevalence of drug-relatedproblems. Therefore, this study aimed to identify drug-related problems of patients receiving TB therapy at the Tebet Subdistrict Health Center fromJuly 2018 to December 2018.Methods: The study was designed as a cross-sectional study using the retrospective data retrieval method from prescriptions of patients withTB from July 2018 to December 2018. The classification system prepared by Cipolle, Strand, and Morley was used for the classification of drugrelatedproblems; this system includes unnecessary drug therapy, required additional drug therapy, ineffective drug, dosage error, and druginteraction.Results: The percentage of unnecessary drug therapy, required additional drug therapy, ineffective drug, dosage error, and drug interaction was2.85%, 6.89%, 1.54%, 12.46%, and 66.18%, respectively, with the occurrence of drug-related problems being the highest.Conclusion: The administration of anti-TB drugs can potentially cause drug-related problems. Therefore, the assessment needs to be optimizedbefore the administration of medications to patients and medications should be prescribed and monitored regularly to achieve rational drug use
Highlights
Tuberculosis (TB) is a highly prevalent communicable disease caused by Mycobacterium tuberculosis [1]
The World Health Organization [2] stated that 9 million individuals were infected by M. tuberculosis in 2013 worldwide
In 2017, 87% of new TB cases occurred in 30 countries and >95% cases of TB-infected individuals in developing countries such as India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa [2]
Summary
Tuberculosis (TB) is a highly prevalent communicable disease caused by Mycobacterium tuberculosis [1]. 1.5 million individuals worldwide die due to M. tuberculosis infection annually. In 2017, 87% of new TB cases occurred in 30 countries and >95% cases of TB-infected individuals in developing countries such as India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa [2]. The compliance with medication intake in patients infected with TB and with other diseases is challenging, leading to multidrug- or rifampicin-resistant (RR) TB (Multidrug resistance [MDR]/RR-TB) [4,5]. Some reasons for this include failure in dose use, indiscipline, and drug interaction with other medicines [6]. Problems mentioned earlier are part of the problems observed in treating patients with TB [2,9,10]
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call